Clinical trial
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent…
NCT00107289 · Memorial Sloan Kettering Cancer Center, Other · Recruiting
Key facts
| NCT number | NCT00107289 |
|---|---|
| Title | Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma |
| Official title | Open Access Protocol of Targeted Radiotherapy With I-metaiodobenzylguanidine (I-MIBG) in Patients With Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroblastoma, Pheochromocytoma |
| Intervention type | Drug |
| Interventions | iobenguane I 131 |
| Enrollment | 200 |
| Start date | May 1, 2006 |
| Primary completion | May 1, 2026 |
| Completion | May 1, 2026 |
| First posted | Apr 6, 2005 |
| Last update posted | Dec 23, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: